Belfius Banque SA 3.25% 18 October 2027 News - BE0002892736

AstraZeneca, Daiichi Sankyo's Enhertu Gets Approval in EU For Lung Cancer Treatment

By Michael Susin AstraZeneca said that its drug Enhertu, which it developed in partnership with Daiichi Sankyo, has been approved in the European...

Merck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 Billion

By Ben Glickman Merck and Daiichi Sankyo agreed to jointly develop and commercialize three potential cancer treatments in a deal worth up to $22...

AstraZeneca Says Trial Results For Breast Cancer Drug Were Highly Positive

By Christian Moess Laursen AstraZeneca said trial results for its breast cancer drug Dato-DXd showed significant improvement for the primary...

AstraZeneca's Lung-Cancer Treatment Gets Recommended for Approval in the EU

By Christian Moess Laursen AstraZeneca said its lung-cancer drug Enhertu has been recommended for approval in the European Union following...

AstraZeneca Says Datopotamab Deruxtecan Combined With Imfinzi Shows High Disease Control Rates

By Anthony O. Goriainoff AstraZeneca and Daiichi Sankyo said that datopotamab deruxtecan, a cancer drug, combined with the Imfinzi cancer...

AstraZeneca Says Datopotamab Deruxtecan Phase 3 Trial Shows Positive Results in Lung Cancer Patients

By Anthony O. Goriainoff AstraZeneca said Monday that its datopotamab deruxtecan treatment showed positive results in patients with advanced...

AstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in Trial

By Elena Vardon AstraZeneca said Monday that the phase II trial for its cancer drug Enhertu showed clinically meaningful and durable responses...

AstraZeneca Says Enhertu Recommended for EU Approval for Gastric Cancer

By Kyle Morris AstraZeneca PLC said Monday that Enhertu has been recommended for approval in the European Union for patients with gastric cancer...

AstraZeneca, Daiichi's Enhertu Approved by the FDA for Lung Cancer Treatment

By Michael Susin AstraZeneca PLC and Daiichi Sankyo Co. have said that their antibody drug Enhertu has been approved by the U.S. Food and Drug...

AstraZeneca Reports Promising Data From Lung Cancer Trial

By Ian Walker AstraZeneca PLC said Tuesday that initial results from a trial of datopotamab deruxtecan-based combinations show promising clinical...

AstraZeneca Enhertu Breast Cancer Drug Is Recommended for EU Approval

By Jaime Llinares Taboada AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients...

AstraZeneca's Enhertu Approved in US for Metastatic Breast Cancer Treatment

By Michael Susin AstraZeneca PLC said on Thursday that its metastatic breast cancer treatment Enhertu has been approved for use in the U.S. The...

AstraZeneca, Daiichi Sankyo Say FDA Has Accepted Enhertu for Priority Review

By Anthony O. Goriainoff AstraZeneca PLC and Daiichi Sankyo Co. said Tuesday that Enhertu, a cancer treatment, has been accepted by the U.S. Food...

AstraZeneca, Daiichi Sankyo Report Positive Trial Results for Enhertu Breast-Cancer Treatment -- Update

By Jaime Llinares Taboada AstraZeneca PLC and Daiichi Sankyo Co. on Monday reported positive Phase 3 trial results for the Enhertu treatment on...

AstraZeneca's Enhertu Granted Priority Review by US Regulator

By Anthony O. Goriainoff AstraZeneca PLC said on Monday that its breast cancer drug, Enhertu, has been granted priority review by the U.S. Food...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Belfius Banque SA 3.25% 18 October 2027 (BE0002892736)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

BE0002892736 News

AstraZeneca, Daiichi Sankyo's Enhertu Gets Approval in EU For Lung Cancer Treatment

Merck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 Billion

AstraZeneca Says Trial Results For Breast Cancer Drug Were Highly Positive

AstraZeneca's Lung-Cancer Treatment Gets Recommended for Approval in the EU

AstraZeneca Says Datopotamab Deruxtecan Combined With Imfinzi Shows High Disease Control Rates

AstraZeneca Says Datopotamab Deruxtecan Phase 3 Trial Shows Positive Results in Lung Cancer Patients

AstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in Trial

AstraZeneca Says Enhertu Recommended for EU Approval for Gastric Cancer

AstraZeneca, Daiichi's Enhertu Approved by the FDA for Lung Cancer Treatment

AstraZeneca Reports Promising Data From Lung Cancer Trial

AstraZeneca Enhertu Breast Cancer Drug Is Recommended for EU Approval

AstraZeneca's Enhertu Approved in US for Metastatic Breast Cancer Treatment

AstraZeneca, Daiichi Sankyo Say FDA Has Accepted Enhertu for Priority Review

AstraZeneca, Daiichi Sankyo Report Positive Trial Results for Enhertu Breast-Cancer Treatment -- Update

AstraZeneca's Enhertu Granted Priority Review by US Regulator

BE0002892736 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Belfius Banque SA 3.25% 18 October 2027 (BE0002892736) News

Belfius Banque SA 3.25% 18 October 2027 (BE0002892736)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

BE0002892736 News

AstraZeneca, Daiichi Sankyo's Enhertu Gets Approval in EU For Lung Cancer Treatment

Merck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 Billion

AstraZeneca Says Trial Results For Breast Cancer Drug Were Highly Positive

AstraZeneca's Lung-Cancer Treatment Gets Recommended for Approval in the EU

AstraZeneca Says Datopotamab Deruxtecan Combined With Imfinzi Shows High Disease Control Rates

AstraZeneca Says Datopotamab Deruxtecan Phase 3 Trial Shows Positive Results in Lung Cancer Patients

AstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in Trial

AstraZeneca Says Enhertu Recommended for EU Approval for Gastric Cancer

AstraZeneca, Daiichi's Enhertu Approved by the FDA for Lung Cancer Treatment

AstraZeneca Reports Promising Data From Lung Cancer Trial

AstraZeneca Enhertu Breast Cancer Drug Is Recommended for EU Approval

AstraZeneca's Enhertu Approved in US for Metastatic Breast Cancer Treatment

AstraZeneca, Daiichi Sankyo Say FDA Has Accepted Enhertu for Priority Review

AstraZeneca, Daiichi Sankyo Report Positive Trial Results for Enhertu Breast-Cancer Treatment -- Update

AstraZeneca's Enhertu Granted Priority Review by US Regulator

BE0002892736 Discussion

Your Recent History